Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy-induced eczema treated with dupilumab.
D'Erme AM, Fidanzi C, Mori N, Musettini G, Cupini S, Barbara C, Allegrini G, Bagnoni G, Janowska A. D'Erme AM, et al. Among authors: musettini g. J Eur Acad Dermatol Venereol. 2024 May;38(5):e447-e449. doi: 10.1111/jdv.19707. Epub 2023 Dec 12. J Eur Acad Dermatol Venereol. 2024. PMID: 38084780 No abstract available.
Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.
Coltelli L, Finale C, Musettini G, Fontana A, Barletta MT, Lucarini AR, Fabiani I, Scalese M, Bocci G, Masini LC, Soria G, Cupini S, Arrighi G, Barbara C, De Maio E, Salvadori B, Marini A, Pellino A, Stasi I, Emdin M, Giaconi S, Marcucci L, Allegrini G. Coltelli L, et al. Among authors: musettini g. Clin Exp Med. 2023 Dec;23(8):5113-5120. doi: 10.1007/s10238-023-01144-8. Epub 2023 Aug 27. Clin Exp Med. 2023. PMID: 37634231 Free PMC article.
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.
Fornaro L, Musettini G, Orlandi P, Pecora I, Vivaldi C, Banchi M, Salani F, Fini E, Massa V, Catanese S, Cucchiara F, Lencioni M, Masi G, Vasile E, Bocci G. Fornaro L, et al. Among authors: musettini g. Am J Cancer Res. 2022 Jul 15;12(7):3347-3356. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968330 Free PMC article.
HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.
Vivaldi C, Fornaro L, Ugolini C, Niccoli C, Musettini G, Pecora I, Cacciato Insilla A, Salani F, Pasquini G, Catanese S, Lencioni M, Masi G, Campani D, Fontantini G, Falcone A, Vasile E. Vivaldi C, et al. Among authors: musettini g. Oncologist. 2020 Oct;25(10):886-893. doi: 10.1634/theoncologist.2019-0922. Epub 2020 May 11. Oncologist. 2020. PMID: 32353192 Free PMC article.
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.
Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A, Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J, Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P, Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F. Fornaro L, et al. Among authors: musettini g. Clin Colorectal Cancer. 2019 Dec;18(4):e394-e401. doi: 10.1016/j.clcc.2019.08.004. Epub 2019 Sep 4. Clin Colorectal Cancer. 2019. PMID: 31564556
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G, Vivaldi C, Fornaro L, Lonardi S, Buccianti P, Sainato A, Marcucci L, Martignetti A, Luca Urso ED, Castagna M, Fontanini G, Bergamo F, Musettini G, Urbani L, Sensi E, Balestri R, Montrone S, Pasqualetti F, Cremolini C, Di Paolo A, Zagonel V, Falcone A. Masi G, et al. Among authors: musettini g. Eur J Cancer. 2019 Mar;110:32-41. doi: 10.1016/j.ejca.2019.01.006. Epub 2019 Feb 7. Eur J Cancer. 2019. PMID: 30739838 Clinical Trial.
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).
Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, Cavanna L, Gori S, Fabi A, Marzano N, Graiff C, De Sanctis V, Mirabile A, Serpentini S, Bocci C, Pino MS, Cilenti G, Verusio C, Ballatori E; NICSO (Network Italiano per le Cure di Supporto in Oncologia). Roila F, et al. Support Care Cancer. 2019 Mar;27(3):1041-1047. doi: 10.1007/s00520-018-4393-9. Epub 2018 Aug 6. Support Care Cancer. 2019. PMID: 30084104
23 results